PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics

Pharmacogenet Genomics. 2018 May;28(5):127-137. doi: 10.1097/FPC.0000000000000331.

Authors

Maria Alvarellos¹, Chantal Guillemette², Russ B Altman^{3

4}, Teri E Klein¹

Affiliations

¹ Departments of Biomedical Data Science.
² Faculty of Pharmacy, University Hospital Center of Quebec (CHU), Laval University, Quebec City, Quebec, Canada.
³ Genetics.
⁴ Bioengineering, Stanford University, Stanford, California, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

ATP Binding Cassette Transporter, Subfamily B / genetics
Atazanavir Sulfate / pharmacokinetics*
Atazanavir Sulfate / therapeutic use
Drug Synergism
Glucuronosyltransferase / genetics
HIV Infections / drug therapy
HIV Infections / genetics*
HIV Protease Inhibitors / pharmacokinetics*
HIV Protease Inhibitors / therapeutic use
Humans
Liver-Specific Organic Anion Transporter 1 / genetics
Pharmacogenetics / methods*
Pregnane X Receptor / genetics
Ritonavir / pharmacokinetics
Ritonavir / therapeutic use

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
HIV Protease Inhibitors
Liver-Specific Organic Anion Transporter 1
NR1I2 protein, human
Pregnane X Receptor
SLCO1B1 protein, human
Atazanavir Sulfate
UGT1A1 enzyme
Glucuronosyltransferase
Ritonavir

Grants and funding